CFDE Data Portal | Search COL9A3

	Label	Description
	COL9A3 Gene (Entity type)	ENSG00000092758 - collagen type IX alpha 3 chain
	COL9A3 associations Collection (Entity type)	Associations for COL9A3_associations
	COL9A3 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

COL9A3

ENSG00000092758 - collagen type IX alpha 3 chain

COL9A3 associations

Associations for COL9A3_associations

COL9A3 associations.tsv

A file from IDG as part of the Harmonizome project

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human up

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.